Treatment options for high-risk early rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial is studying different treatments for patients with early-stage rectal cancer that has a higher chance of coming back after local removal. It looks at whether adding radiation or chemoradiation after local surgery can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your rectal tumor was removed locally (not through major surgery) and is stage pT1 with high-risk features like poor differentiation or deep invasion.
- You have no cancer spread to lymph nodes or other organs (confirmed by CT scan).
- You are able to start radiation or chemoradiation within 12 weeks of the local surgery.
- You have not had previous rectal surgery (other than local excision) or pelvic radiation.
- You agreed to avoid standard major surgery (TME) after being informed about it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy before surgery for high-risk rectal cancer. The goal is to see if this combination shrinks the tumor more effectively and improves outcomes.
This trial compares standard chemotherapy to more extensive surgery (total mesorectal excision) for patients whose initial local surgery showed high-risk features like poor differentiation, lymphovascular invasion, or larger tumor size. It aims to find the best treatment to prevent cancer from coming back.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This trial tests a combination of radiation, chemotherapy, and immunotherapy drugs before surgery for people with locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients with higher-risk disease.
This trial tests giving targeted radiation, chemotherapy, and immunotherapy before surgery to shrink locally advanced rectal cancer. It aims to improve treatment results for patients whose tumors have not spread but are at high risk of coming back.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.